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Brandon K. C. Au,1 Margaret A. Au,2 Jason W. Chien3,4Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell trans-
plantation (aHCT). Recent National Institutes of Health consensus diagnostic criteria for BOS have not been
assessed in a clinical setting. Modified National Institutes of Health diagnostic consensus criteria for BOS
were applied to evaluate its prevalence, risk factors, and outcomes in the modern era of aHCT. Pulmonary
function tests from 1145 patients were screened to identify patients with new-onset airflow obstruction.
Clinical records were reviewed to exclude pulmonary infection and other causes. The overall prevalence
of BOS among all transplanted patients was 5.5%, and 14% among patients with chronic graft-versus-host
disease (cGVHD). The median time from transplant to meeting spirometric criteria for BOS was 439 days
(range: 274-1690). Although many previously identified risk factors were not significantly associated, lower
baseline FEV1/FVC ratio (P5 .006), non-Caucasian race (P5 .014), lower circulating IgG level (P5 .010), and
presence of cGVHD (P\ 0.001) were associated with an increase in risk, with the latter associated with
a 10-fold increase in risk. Multivariate analysis indicated that BOS conferred a 1.6-fold increase in risk for
mortality after diagnosis. These results suggest that the National Institutes of Health diagnostic criteria
can reliably identify BOS, and that it is more prevalent than previously suggested. Spirometric monitoring
of high-risk patients with cGVHD may permit earlier detection and intervention for this often-fatal disease.
Biol Blood Marrow Transplant 17: 1072-1078 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Bronchiolitis obliterans syndrome, Chronic graft-versus-host disease, Allogeneic hemato-
poietic cell transplantationINTRODUCTION
Bronchiolitis obliterans syndrome (BOS) is a lung
complication of allogeneic hematopoietic cell trans-
plantation (aHCT) recipients that is characterized
clinically by the development of fixed new-onset
airflow obstruction (AFO) and pathologically by
progressive circumferential fibrosis targeting the ter-
minal bronchioles. Because BOS is always observed
in the presence of chronic graft-versus-host disease
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6/j.bbmt.2010.11.018transplantation as host-versus-graft disease, it is likely
that BOS is caused by an alloimmune response of
donor hematopoietic cells against host lung antigens.
Although BOS patients are typically treated with im-
munosuppressive agents, there is no strong evidence
that any specific therapies are effective in improving
long-term outcomes. Patients affected by BOS carry
a poor prognosis, with an overall 2-year survival rate
of 44% to 45% and a 5-year survival rate of 13% [1-3].
There ismuch variation in the estimated prevalence
of BOS.Most studies estimate the prevalence of BOS to
be 2% to 3% among aHCT recipients, or 6% among
patients with cGVHD [2,4-6]. However, some suspect
the prevalence of BOS may be as high as 10% to 20%
[3,7,8]. This variability in prevalence estimates is
largely because of a lack of consensus regarding the
clinical diagnostic criteria for BOS. Indeed, there are
at least 10 distinct clinical definitions for BOS after
aHCT in the published literature [2,7,9-15].
In 2005, the National Institutes of Health (NIH)
proposed new consensus diagnostic criteria for BOS,
defining this syndrome by the presence of 4 clinical
characteristics: (1) forced expiratory volume in 1
second (FEV1)\75% predicted, (2) FEV1/forced vital
capacity (FVC) ratio\0.7, (3) evidence of air trapping,
small airway thickening, or bronchiectasis on high-
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volume (RV) .120% of predicted normal and (4)
absence of respiratory tract infection, or pathologic
confirmation [11]. Recommendations for modifying
the NIH criteria were recently made to improve the
diagnostic accuracy of the consensus criteria [16].
The purpose of the current study is to use these recom-
mendations to assess the prevalence, risk factors, and
outcomes of BOS in a cohort of aHCT recipients.
MATERIALS AND METHODS
This retrospective study was approved by the insti-
tutional review board at the Fred Hutchinson Cancer
Research Center (FHCRC). All patients who received
their first aHCT at the FHCRC/Seattle Cancer Care
Alliance (SCCA) between January 1, 2002, and June
30, 2006, were eligible for this study. The medical re-
cords of all patients who met spirometric criteria for
BOS were reviewed for additional clinical, radiologic,
microbiologic, and treatment data. All patients were
evaluated for respiratory infection according to
standard clinical protocol. When indicated, additional
investigations for infection such as nasal wash, sputum
culture, and bronchoscopies were performed. Assays
for bacterial, viral, and fungal pathogens were
routinely performed on all bronchoalveolar lavages.
Details regarding the clinical data and infectious
evaluation are available in the online supplement.
BOS patients were classified according to recogni-
tion status as concurrently recognized, late recognized,
or never recognized. Concurrent clinical recognition
was defined as clinical documentation of BOS in the
medical records within 1 month of meeting NIH spi-
rometric criteria. Late recognized was defined as docu-
mentation in the medical records of BOS .1 month
of meeting NIH spirometric criteria. Never recognized
was defined as the absence of documentation of BOS
in the available FHCRC and non-FHCRC medical
records despite meeting NIH spirometric criteria.
Pulmonary Function Testing
To avoid misclassification because of reversible
changes in lung functionduring thefirst year after trans-
plant, only pulmonary function tests (PFTs) obtained at
or after 1 year posttransplant (365 6 100 days) were
evaluated for BOS. As part of clinical protocol, all pa-
tients who return for a 1-year evaluation receive
a PFT.However, after the first year, PFTs are obtained
at the discretion of their primary physician. For all
PFTs, predicted values were calculated using published
equations for children andadults [17,18]. All pulmonary
function values, except for the FEV1/FVC ratio, were
expressed as a percentage of predicted values.
One-year posttransplant PFTs were defined at 365
6 100 days. Patients surviving to at least 1 year (6100
days) were screened for BOS using modified NIHspirometry criteria: (1) FEV1 \75% predicted, (2)
FEV1/FVC ratio\0.7, and (3) decrease of the FEV1
by$10% in comparison to the pretransplant value. Pa-
tientswere required tomeet all 3 criteria to pass this first
screen. Postbronchodilator values were used whenever
available to minimize misclassification of reversible
AFO. The date of the initial PFT fulfilling the above-
modified NIH spirometry criteria was used as the date
of BOS diagnosis, with the exception of those that
were reclassified as noncases following chart review.
Pulmonary function at the time of meeting NIH
spirometry criteria and after was quantified using the
NIH recommended lung function score (LFS). The
LFS was calculated using the FEV1 and carbon mon-
oxide diffusion capacity (DLCO) ($80% 5 1, 70%-
79% 5 2, 60%-69% 5 3, 50%-59% 5 4, 40%-49%
5 5, and \40% 5 6) [11]. Scores for FEV1 and
DLCO were then summed, categorized from 0 to 3,
and defined according to NIH recommendations
(LFS score 2 5 category 0 [normal]; LFS score 3-5
5 category 1 [mildly abnormal]; LFS score 6-9 5 cat-
egory 2 [moderately abnormal]; or LFS score 10-125
category 3 [severely abnormal]).
Statistical Methods
All statistical analyses were performed using
STATA 10.0 (StataCorp, College Station, TX) and R
2.6.2. Two-sided P values \.05 were considered
statistically significant. t-Tests were performed to
compare baseline PFTmeasurements in cases and non-
cases. Univariate analyses were performed using Pear-
son’s chi-square test. Covariates with P \ .1 in
univariate analyses were considered in multivariate
Cox regression using backward stepwise regression to
assess their impact on risk for BOS. Chronic GVHD
and acute GVHD (aGVHD) were treated as time-
dependent covariates. Both unadjusted and adjusted
(for age, disease risk, and time-dependent cGVHD
and aGVHD) models were fitted to evaluate the effect
of BOS on risk of nonrelapsemortality. Cumulative in-
cidence of BOS was calculated considering death, re-
lapse, and second transplant as competing risks. The
Kaplan-Meier method was used to estimate overall
nonrelapse survival in BOS cases. Stratified Kaplan-
Meier curves were also calculated to investigate group
survival trends in variables of interest. The log-rank
test was used to evaluate survival differences across
groups. Treatment for BOS was assessed using a Cox
model among all BOS cases. Mean changes in LFS
were compared among recognition and treatment
groups using analysis of variance (ANOVA).
RESULTS
Cohort Characteristics
Between January 1, 2002, and June 30, 2006, 1145
patients received a first-time aHCT. Thirty-nine
Table 1. Clinical Characteristics of the BOS and Non-BOS
Cases from the Study Cohort
Clinical Variables
BOS (%)
n 5 63
Non-BOS (%)
n 5 883 P Value
Age, median (range): Median 48.2
years, range
(14, 67.2)
median 48.3
years, range
(13, 74.5)
.474
Male/female ratio 1: 0.6 1: 0.7 .484
Sex match, donor-recipient
Female—male 22 (35) 230 (26) .395
Female—female 13 (21) 172 (20)
Male—male 18 (29) 291 (33)
Male—female 10 (16) 189 (21)
Race 71% White 84% White .014
Disease risk at transplant
Low 12 (19) 130 (15) .623
Intermediate 26 (41) 400 (45)
High 25 (40) 353 (40)
Donor HLA status
Matched/related 34 (54) 477 (64) .778
Mismatched/related 20 (32) 245 (33)
Unrelated 1 (2) 23 (3)
Stem cell source
Bone marrow 59(94) 749 (85) .155
PBSC 4 (6) 130 (15)
Other 0 (0) 4 (1)
Cytomegalovirus serologic
status, recipient-donor
Negative-negative 20 (32) 262 (30) .320
Negative-positive 9 (14) 109 (12)
Positive-negative 12 (19) 262 (30)
Positive-positive 22 (35) 248 (28)
Conditioning regimens
Reduced intensity 26 (41) 312 (35) .319
Myeloablative 37 (59) 571 (65)
TBI 9 (56) 195 (34)
Non-TBI 28 (44) 376 (66)
Busulfan-based conditioning
regimen
27 (43) 356 (43) .692
Acute GVHD grade
0/1/2 60 (95) 745 (87) .061
3 3 (5) 109 (13)
Chronic GVHD
Positive 63 (100) 444 (65) <.001
Negative 0 (0) 240 (35)
Baseline FEV1
$80% 47 (75) 712 (81) .071
70%-79% 10 (16) 96 (11)
60%-69% 6 (10) 36 (4)
<60% 0 (0) 23 (3)
Smoking
Never 7 (11) 128 (15) .623
Former 1 (2) 37 (4)
Current 0 (0) 10 (1)
Prior interstitial pneumonitis 2 (3) 91 (10) .066
GVHD indicates graft-versus host disease; PBSC, peripheral blood stem
cells; TBI, total-body irridiation; BOS, bronchiolitis obliterans syndrome;
FEV1, forced expiratory volume in 1 second.
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of missing pretransplant PFTs, and 160 were excluded
because of missing 1-year posttransplant PFTs. The
remaining 946 subjects are described in Table 1. A to-
tal of 2999 PFTs (946 pretransplant, 2053 posttrans-
plant) were evaluated; 2350 local and 649 nonlocal
PFTs were screened using theNIH spirometry criteria
for BOS. Pretransplant PFTs were obtained at a mean
of 30 days prior to transplant.
BOS Prevalence
Initial screening identified 102 patients who met
the NIH criteria for new-onset AFO. Fourteen cases
were removed because of invalid PFT results caused
by procedural error. One case was excluded because
the patient developed AFO following 2 aHCTs. An
additional 24 cases were excluded because of alterna-
tive diagnoses including pneumonia (n5 3), restrictive
lung disease (n5 9), sinusitis (n5 3), bronchiolitis ob-
literans with organizing pneumonia (BOOP) (n 5 4),
asthma (n 5 3), and interstitial pneumonitis (n 5 2),
and no clinical data to support the presence of BOS.
Among the remaining 63 cases, 33 (52%) had both
lung volume measurements and HRCT scans of the
chest available at the time of meeting spirometric cri-
teria. Of these, 30 (91%) met full NIH criteria for
BOS: 7 had a RV .120% alone, 6 had a RV #120%
but HRCT findings consistent with BOS, and 17 had
both a RV .120% and HRCT findings consistent
with BOS. Two (6%) patients had evidence of BOS
on HRCT but no lung volume measurements were
documented. Supportive HRCT findings included 14
(22%) with air trapping, 1 (2%) with bronchiectasis,
1 (2%) with bronchial wall thickening, 1 (2%) with
centrilobular opacities, and 8 (13%) with a combina-
tion of these findings. There were an additional 23 pa-
tients who had lung volumes, but not HRCT, available
either at the time of meeting spirometric criteria or
subsequently. Of these, 22 (96%) had a RV .120%
andmet full NIH criteria for BOS. Four of the patients
who met full NIH criteria for BOS also received a his-
topathological diagnosis by lung biopsy. Of the re-
maining 9 patients, none had received an HRCT and
3 were missing lung volume measurements. Neverthe-
less, 5 of these patients were clinically recognized as
having BOS. In total, 59 (94%) of these 63 patients
met full NIH criteria for BOS or were clinically recog-
nized as having BOS, and the remaining 4 patients met
the NIH spirometric criteria for BOS. For the remain-
der of this report, all 63 patients were considered to
have confirmed BOS.
The overall prevalence of BOS for all patients
receiving an aHCT (n 5 1145) was 5.5%. The preva-
lence of BOS among patients who developed cGVHD
(n 5 450) was 14%. The cumulative incidence curve
for BOS with death as a competing risk is displayed
in Figure 1; the majority of cases developed between300 and 600 days posttransplant. The median time
from transplant to meeting spirometric criteria for
BOS was 439 days (range: 274-1690). Among the 63
BOS patients, 52 cases were clinically recognized
whereas 11 were clinically unrecognized. Of the 52
clinically recognized cases, 38 were recognized con-
currently whereas 14 were recognized late, at a median
time of 294 days (range: 92-1219) after meeting spiro-
metric criteria. The concurrently recognized cases in-
cluded 4 patients who were clinically diagnosed with
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Figure 1. Cumulative incidence of BOS among all transplanted patients
considering death as a competing risk.
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were available. The median times to meeting spiro-
metric criteria for the concurrently recognized, late
recognized, and never recognized groups were 389
(range: 274-1690), 492 (range: 301-1217), and 719
(361-1685) days, respectively.BOS Clinical Characteristics
The majority (n 5 38, 60%) of BOS patients had
no evidence of prior pulmonary disease. Twenty-five
BOS patients had a documented prior medical history
of pulmonary disease including 4 (6%) with chronic
obstructive pulmonary disease (COPD), 4 (6%) with
asthma, 4 (6%) with chronic allergic rhinitis/sinusitis,
3 (5%) with radiation-induced lung injury, 2 (3%) with
pretransplant BOOP, 1 (1.6%) each with POEMS syn-
drome, pulmonary embolus, diffuse alveolar hemor-
rhage, or obstructive sleep apnea, and 4 (6%) with
multiple diseases. Chart review also revealed that 1
BOS patient had a coexisting cryptogenic organizing
pneumonia at the time of diagnosis. This case was
pathologically confirmed.
Among BOS cases, the pretransplant median per-
cent predicted FEV1was 87% (range: 62-114), the me-
dian FEV1/FVC ratio was 0.76 (range: 0.64-0.87), and
themedian percentage predicted RVwas 106% (range:
57-203). In comparison, noncases had higher FEV1
values (median: 93%, range: 29-132, P 5 0.025) and
FEV1/FVC ratios (median: 0.79, range: 0.53-1.00, P
5 .0013), with similar percent of predicted RV values
(median: 104%, range: 36-298, p5 .5598). More BOS
patients had a ratio\0.7 prior to transplantation (22%
versus 11%, P 5 .008). Table 2 summarizes PFT
characteristics at time of meeting NIH criteria accord-
ing to recognition status. Recognized cases tended to
have lower FEV1 compared to never recognized cases
(P 5 .049), and concurrently recognized cases had the
highest magnitude of air trapping compared to the
other groups (P5 .008). Although the LFS of the con-currently recognized patients appeared to be worse
than the late and never recognized patients, this was
not statistically significant (P 5 .45).
All BOS cases were either concurrently (n5 62) di-
agnosed with cGVHD or diagnosed with cGVHD
within 2 months after meeting NIH spirometric crite-
ria (n 5 1). Among the 52 clinically recognized cases,
cGVHD status at the time of recognition included
31 with active cGVHD, 19 stable, 1 quiescent, and 1
without cGVHD. Sixty patients were on immunosup-
pression within the 3 months prior to meeting the
NIH spirometric criteria; of these, 30 (48% of total
BOS cases) were on an immunotherapy taper, whereas
8 were on a stable regimen, 3 were increased, and 19
were fluctuating. For those on immunotherapy tapers,
these included systemic corticosteroids, tacrolimus,
cyclosporine, and mycophenolate mofetil.
Risk Factors for BOS
Univariate analysis showed that BOS was not sig-
nificantly associated with many previously identified
risk factors for BOS, including a busulfan-based regi-
men (P 5 .692), peripheral blood stem cell source
(P 5 .155), donor-recipient gender mismatch (P 5
.395), use of methotrexate for GVHD prophylaxis
(P5 .678), or respiratory viral infection within the first
100 days posttransplant (P5 .376). However, BOSwas
significantly associated with cGVHD (P\ .001), lower
baseline FEV1/FVC ratio (P 5 .006), non-Caucasian
race (P 5 .014), and lower circulating IgG level (P 5
.010), and borderline associated with lower baseline
FEV1 (P 5 .071), lack of history of pneumonitis (P 5
.066), and absence of aGVHD (P 5 .061) (see Table
1). Additional analysis of IgG level revealed that this
relationship was most significant when IgG levels
were #350 ng/dL (hazard ratio [HR]: 2.28, 95% con-
fidence interval [CI]: [1.31, 3.96], P 5 .003). Univari-
ate Cox regression analysis of the effect of cGVHD
as a time-dependent covariate on risk of BOS revealed
a HR for cGVHD of 10.65 (95% CI: [3.33, 34.02],
P \ .001). Multivariate analysis that considered all
the variables in Table 1 with a P value \ .1 level,
with the exception of FEV1/FVC ratio, which was co-
linear with baseline FEV1, revealed that only cGVHD
and lower IgG levels remained significant risk factors
for BOS (Table 3).
Treatment and Outcomes for BOS
Of the 52 clinically recognized BOS cases, only 1
patient did not receive immunosuppressive therapy
immediately following clinical diagnosis. Of the 51 pa-
tients who did receive therapy, 39 were intentionally
treated for BOS, whereas 12 were monitored with
a watchful waiting approach (no change in immunosup-
pressive regimen) but were kept on immunosuppression
for coexisting cGVHD. Among those intentionally
Table 2. Pulmonary Function and Clinical Characteristics of BOS Patients at Time of Meeting NIH Criteria Based upon Clinical
Recognition Status
Measure
Concurrent
n 5 38
Late
n 5 14
Unrecognized
n 5 11
P value*
All Cases
N 5 63
Median Range Median Range Median Range Median Range
FEV1 (%) 58% (16%, 74%) 57% (38%, 74%) 64% (44%, 73%) .1750 59% (16%, 74%)
FVC (%) 73% (41%, 99%) 72% (46%, 97%) 75% (57%, 91%) .5871 73% (41, 99%)
FEV1/FVC ratio 0.61 (0.29, 0.69) 0.58 (0.46, 0.68) 0.64 (0.54, 0.69) .0646 0.63 (0.29, 0.69)
TLC (%) 99% (75%, 153%) 96% (64%, 120%) 90% (66%, 119%) .3360 96% (64, 153%)
RV (%) 155% (65%, 334%) 113% (62%, 195%) 116% (57%, 163%) .0275 135% (57%, 334%)
DLCO (%) 66% (34%, 95%) 59% (9%, 98%) 60% (24%, 104%) .2896 63% (9%, 104%)
LFS 9 (4, 12) 9 (4, 12) 8 (4, 11) .2282 9 (4, 12)
DLCO indicates carbon monoxide diffusion capacity; LFS, lung function score; RV, residual volume; BOS, bronchiolitis obliterans syndrome; FVC; forced
vital capacity; FEV1, forced expiratory volume in 1 second.
*P values were calculated using the Kruskal-Wallis test to compare the medians of the concurrent, late, and unrecognized groups.
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kg/day, 23 received inhaled corticosteroids, 11 received
azithromycin, and in rare cases, montelukast (n5 3) or
ECP (n5 1) were also administered. Most of these pa-
tients also received other immunosuppressants for coex-
isting cGVHD in other organs, including low-dose
systemic corticosteroids, tacrolimus, cyclosporine, siro-
limus, mycophenolate mofetil, ECP, azathioprine, and
methotrexate. For the never recognized BOS cases, all
11 of them were on immunosuppressive therapies for
coexisting cGVHD after meeting spirometric criteria
for BOS.
Survival analysis revealed a significant difference
between subjects with and without BOS (p 5 0.002;
see Figure 2A). Subanalysis of the BOS patients
revealed that all of the deaths occurred among patients
with clinically recognized BOS. Although all patients
without clinically recognized BOS survived the
follow-up period, patients in the concurrently recog-
nized group had the worst transplant-related mortality
(TRM), followed by the late-recognized group (P 5Table 3. Multivariate Cox Regression for Risk of BOS
Variable HR (95% CI) P Value
Pretransplant FEV1
>80% Referent —
70-79% 1.15 (0.50, 2.65) .745
60-69% 1.59 (0.62, 4.10) .338
<60% — —
Prior interstitial Pneumonitis
No Referent —
Yes 3.97 (0.84, 18.68) .081
Chronic GVHD*
No Referent —
Yes 8.51 (2.63, 27.48) <.001
Acute GVHD*
No Referent —
Yes 0.43 (0.13, 1.47) .178
IgG level (ng/dL)
IgG $350 Referent —
IgG <350 1.92 (1.09, 3.39) .024
CI indicates confidence interval; GVHD, graft-versus-host disease; BOS,
bronchiolitis obliterans syndrome; HR, hazard ratio; FEV1, forced expi-
ratory volume in 1 second.
*Chronic and acute GVHDwere included as time-dependent covariates..022; Figure 2B). Unadjusted analyses of TRM
estimated HR for BOS of 2.19 (95% CI: [1.32, 3.65],
P 5 .002), and were 3.29 (95% CI: [1.91, 5.67], P\
.001) and 1.58 (95% CI: [0.50, 5.01], P 5 .77) when
stratified for the concurrently recognized and late-
recognized BOS groups, respectively. When adjusted
for cGVHD and aGVHD, age, conditioning regimen,
disease risk, and cytomegalovirus (CMV) serostatus,
the estimated HR for BOS decreased to 1.62 (95%
CI: [1.03, 2.55], P 5 .035). TRM did not differ signif-
icantly between cases that did or did not receive inten-
tional therapy for BOS (P 5 .708). TRM also did not
differ significantly based on treatment regimen that
specifically included high-dose systemic corticoste-
roids (P 5 .136), inhaled corticosteroids (P 5 .857),
or azithromycin (P 5 .417) when compared to treat-
ment regimens that did not. We also did not find evi-
dence of significant differences in nonrelapse survival
between LFS categories at diagnosis (P 5 .222).
Among patients who had PFTs available at 1 year
(n5 36) and 2 years (n5 23) after meeting BOS crite-
ria, we evaluated the change in LFS among survivors.
There was no difference in the change in LFS at 1
and 2 years after BOS diagnosis when comparing the
clinically recognized versus clinically unrecognized
patients. The mean change in LFS for clinically recog-
nized and unrecognized patients was 20.313 6 2.264
and 0.250 6 2.500 at 1 year (P 5 .646) and 20.409
6 2.720 and21.0006 0.000 at 2 years (P5 .834), re-
spectively. There was also no significant difference in
change of the LFS based upon treatment group. The
mean change in LFS among patients who received
and did not receive intentional therapy was 20.375
6 2.722 and 20.292 6 2.156 at 1 year (P 5 .930)
and 22.000 6 3.347 and 0.188 6 2.287 at 2 years
(P 5 0.093), respectively.
We reviewed the charts of the patients who died af-
ter meeting the BOS criteria to determine the causes of
death. Among 22 patients who died, 11 had a single
cause of death, 8 weremultifactorial, and 3 had no doc-
umentation of a cause of death. BOS was recognized as
contributing to the cause of death in 11 (50%) of these
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Figure 2. (A) Kaplan-Meier survival estimates of transplant-related
mortality comparing BOS to non-BOS cases (P 5 .002). Noncases are
denoted by a solid line, cases are shown as a dashed line. (B) Kaplan-
Meier survival estimates of transplant-related mortality based on clinical
recognition status among BOS cases (P 5 .022). Concurrently recog-
nized cases are denoted by a dashed line, late recognized cases with
a solid line, and never recognized cases with a dotted line.
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whereas 6 were multifactorial (disease relapse,
GVHD, infection, pneumothorax). Other causes of
death were disease relapse (n 5 3), infection (n 5 2),
coronary artery disease (n 5 1), relapse, GVHD alone
(n 5 1), and infection and GVHD (n 5 1).DISCUSSION
This study represents the first evaluation of BOSus-
ing the recent 2005NIHconsensus criteria todetermine
theprevalence, risk factors, andoutcomes forBOS in the
modern age of aHCT. Based upon our results, the 2005
NIH guidelines appear to be reliable for identifying
BOS. However, meeting the spirometric criteria alone
was nonspecific—obtaining HRCT and lung volumes
as part of a clinical workup is essential, as demonstrated
by the fact that, among the BOS cases in our study who
had both HRCT and lung volumes available, 100% ul-
timately met full NIH criteria for BOS.
The overall prevalence for BOS in our patient pop-
ulation was nearly threefold higher than themost com-
prehensive study published using the International
Bone Marrow Transplant Registry, which found the
prevalence of BOS to be 1.7% [6]. Our higher preva-lence may be attributable to our different study design
and use of a different BOS definition. However, there
is compelling evidence to suggest that even the never
recognized patients were indeed true BOS cases. On
average, the 11 clinically unrecognized patients experi-
enced a 23% drop in their FEV1. A review of charts
and clinical data revealed no alternative explanations
for such a profound fixed decline in lung function. In
addition, 5 of these 11 patients actually had evidence
of air trapping on PFT and/or HRCT, allowing
them to fully meet the NIH criteria for BOS.
The magnitude of the hazard for development of
BOS associated with cGVHD was higher than antici-
pated. This finding provides strong support for the
long-accepted hypothesis that BOS, which is also ob-
served after lung transplantation, represents an alloim-
mune reaction in the lung. We were not surprised by
the significantly increased risk for BOS associated
with lower pretransplant lung function, which others
and we have documented in previous studies [3,19].
The association of BOS with lower circulating IgG
levels, which clearly demonstrated a threshold effect,
is consistent with observations from prior studies
[4,10]. Although this association might be explained
by increased susceptibility to infection, the mechanism
by which lower circulating IgG levels might
influence BOS risk is currently unknown and
deserves additional attention.
Most surprising was the lack of significant associa-
tion with many previously reported risk factors for
BOS, including busulfan-based regimen, peripheral
blood stem cell source, donor-recipient gender mis-
match, aGVHD, prior history of pneumonitis, and
early posttransplant respiratory viral infection. This
observation might be related to 2 possibilities. First,
our study may be simply underpowered to detect an
association with the majority of these risk factors. We
suspect this is unlikely given that most of the previous
studies that documented these associations were
performed using much smaller cohorts. A more likely
explanation again is that all of the previous studies
were conducted using several different BOSdefinitions.
Althoughour analysis foundno significant difference
in lung function change between patients who did and
did not receive specific treatment targeted toward BOS,
it is likely that these observations were subject to signifi-
cant selection bias influenced by clinical symptoms.
Therewas also awide variation in theuse of immunosup-
pressive agents for other manifestations of cGVHD,
which made it difficult to accurately account for
treatment-specific outcomes in this retrospective analy-
sis. Any meaningful data regarding treatment response
need to come from future controlled clinical trials.
Our mortality observations based on recognition
status may have significant clinical implications. The
mortality analysis demonstrated that patients whose
BOS was clinically recognized without delay had the
1078 Biol Blood Marrow Transplant 17:1072-1078, 2011B. K. C. Au et al.worst survival. Because almost all of these patients
received immunosuppressive therapy, one might expect
these patients to have the best outcomes. However, it is
more likely that the aggressive nature of these cases al-
lowed the clinicians to easily recognize the syndrome.
Conversely, our data also suggest that the clinically un-
recognized patients remained such because they had
a relatively milder and stable, albeit fixed, manifestation
of BOS. Together, these results suggest that BOS may
present along a clinical spectrum rather than manifest-
ing as a single, unvarying disease.
There are a few limitations worthy of discussion.
First, our retrospective study design limited availabil-
ity of clinical data, making it impossible to gather all
preferred clinical studies for assessment of the NIH
criteria; for example, only 36 out of 63 BOS cases re-
ceived an HRCT. For this reason, we took a primary
approach of BOS screening through inclusion by
NIH spirometric criteria and exclusion of alternative
diagnoses, such as infection, by chart review. Second,
exclusion of patients from the final study cohort be-
cause of missing PFT data may result in underestima-
tion of the prevalence of BOS. Similarly, the current
definition is also likely to miss patients who develop
AFO in the setting of a restrictive process such as
sclerotic skin GVHD, which can mask the obstructive
pattern on PFTs. Thus, it remains possible that the
prevalence in this study still represents an underesti-
mation of the true prevalence of BOS.
Despite the availability of diagnostic criteria for
BOS, our analysis suggests that BOS remains difficult
to diagnose.We agree that pulmonary function testing
andHRCT should play a significant role in diagnosing
BOS and should guide treatment decisions, especially
among patients with cGVHD during the first 2 years
posttransplant. Future research in this area needs to fo-
cus on early detection of BOS and identifying the most
effective and least morbid treatment regimens. If the
risk-benefit ratio can be shifted toward decreased
harm, physicians and patients may be more willing to
treat BOS detected at an earlier stage, when lung func-
tion is more likely to be recovered and higher quality of
life is more likely to be preserved.ACKNOWLEDGMENTS
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